Filing Flows › Supernus Pharmaceuticals (SUPN) › Q3 2026
Supernus Pharmaceuticals (SUPN) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 29, 2026
Supernus Pharmaceuticals (SUPN) reported revenue of $227M for the third quarter 2026 (Q3 2026), +18% from a year earlier and +4% from the quarter before. Operating margin was 9.3%, net earnings $20.9M (9.2% of revenue).
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $227M | +4% | +18% |
| Operating profit | $21.2M | — | — |
| Net earnings | $20.9M | — | — |
| Operating cash flow | $6.6M | — | — |
| Free cash flow | $6.4M | — | — |
What changed
Revenue was $226.8M in Q3 2026, up 18% year over year and up 4% from the previous quarter. Qelbree was the largest line at 40% of revenue. Collaboration revenue (ZURZUVAE) added $21.5M year over year (up 107%), 62% of the total change. Other declined 52%.
Operating profit was $21.2M, a 9.3% margin (up 40.7 points year over year). Total costs fell 19% while revenue rose 18%. The fastest-growing cost line was Cost of revenue (+42%). Net earnings were $20.9M. The effective tax rate was 7.9%.
Operating cash flow was $6.6M, 32% of net earnings. Non-cash charges added back $23.6M of depreciation and amortization and $8.9M of share-based compensation. Working capital and other items used $46.9M. Capital expenditures of $230K left free cash flow of $6.4M.
Questions
What was Supernus Pharmaceuticals' revenue in the third quarter 2026?
Supernus Pharmaceuticals (SUPN) reported revenue of $227M for the third quarter 2026 (Q3 2026), +18% from a year earlier and +4% from the quarter before.
Was Supernus Pharmaceuticals profitable in the third quarter 2026?
Operating profit was $21.2M (9.3% of revenue) and net earnings $20.9M.